Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy
The JPML centralized this docket before Judge Karen S. Marston in the Eastern District of Pennsylvania in December 2025 to consolidate claims that GLP-1 receptor agonist medications caused non-arteritic anterior ischemic optic neuropathy, a form of sudden and typically permanent vision loss, as a distinct proceeding from the earlier, larger GLP-1 RAs MDL before the same judge covering gastroparesis and other gastrointestinal injury claims. With 216 actions pending roughly nine months after centralization, this is a young docket by volume, but its very existence as a separate proceeding is itself a meaningful structural fact.
When the JPML splits out a narrower injury theory into its own MDL rather than folding it into an existing proceeding for the same drug class, it typically reflects a judgment that the new theory raises sufficiently distinct scientific, medical, or evidentiary questions to warrant separate case management — even while assigning the same judge to preserve some institutional continuity on drug-class-wide issues common to both dockets, such as regulatory history and manufacturer conduct. That structure suggests NAION causation will need its own dedicated general-causation record, built on ophthalmologic and neuro-ophthalmologic evidence distinct from the gastrointestinal science developed in the sibling proceeding.
At this early stage, the primary structural questions are how quickly this docket accumulates additional claims as awareness grows, how the court sequences its own case-management schedule relative to the more advanced sibling GLP-1 gastroparesis litigation, and whether the two proceedings share any coordinated discovery on issues common to the drug class even as they litigate their distinct causation theories separately. Criterica Intelligence's platform tracks exactly this kind of related-but-distinct docket structure — how the JPML organizes overlapping drug-class litigation into separate proceedings — across every active MDL, without predicting either docket's causation outcome.
Splitting out a narrower injury theory into its own proceeding typically reflects a judgment that it raises distinct scientific and evidentiary questions warranting separate case management, even while keeping the same judge for institutional continuity on drug-class issues.
It is a form of sudden, typically permanent vision loss caused by reduced blood flow to the optic nerve. It is the specific injury theory at issue in this docket, distinct from the gastrointestinal claims in the related GLP-1 MDL.
They may coordinate on discovery issues common to the drug class, such as regulatory history and manufacturer conduct, even while litigating their distinct causation theories on separate tracks.
How quickly it accumulates additional claims, and how the court sequences its case-management schedule relative to the more procedurally advanced sibling GLP-1 gastroparesis litigation.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.